866-997-4948(US-Canada Toll Free)

Major Depressive Disorder - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Diseases & Conditions

No. of Pages : 200 Pages

Global Markets Direct’s, ‘Major Depressive Disorder - Pipeline Review, H1 2014’, provides an overview of the Major Depressive Disorder’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Major Depressive Disorder
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Major Depressive Disorder and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Major Depressive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Major Depressive Disorder pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Introduction
Global Markets Direct Report Coverage
Major Depressive Disorder Overview
Therapeutics Development
Pipeline Products for Major Depressive Disorder - Overview
Pipeline Products for Major Depressive Disorder - Comparative Analysis
Major Depressive Disorder - Therapeutics under Development by Companies
Major Depressive Disorder - Therapeutics under Investigation by Universities/Institutes
Major Depressive Disorder - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Major Depressive Disorder - Products under Development by Companies
Major Depressive Disorder - Products under Investigation by Universities/Institutes
Major Depressive Disorder - Companies Involved in Therapeutics Development
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
AstraZeneca PLC
Eli Lilly and Company
Alkermes Plc
Dainippon Sumitomo Pharma Co., Ltd.
Taisho Pharmaceutical Co., Ltd.
Neurocrine Biosciences, Inc.
Richter Gedeon Nyrt.
H. Lundbeck A/S
OPKO Health, Inc.
Neuralstem, Inc.
Suven Life Sciences Ltd.
e-Therapeutics plc
Intas Pharmaceuticals Ltd.
Angelini Group
Fabre-Kramer Pharmaceuticals, Inc.
Dart NeuroScience LLC
M\'s Science Corporation
BrainCells Inc.
Otsuka Holdings Co., Ltd.
Reviva Pharmaceuticals Inc.
Luye Pharma Group Ltd.
Euthymics Bioscience, Inc.
Naurex, Inc.
PharmaNeuroBoost NV
NeurOp Corporation
Edgemont Pharmaceuticals, LLC
Methylation Sciences Inc.
Sunovion Pharmaceuticals Inc.
BRAINco Biopharma, S.L.
Bionure
Cerecor Inc.
nLife Therapeutics, S.L.
Aniona ApS
Major Depressive Disorder - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
vortioxetine - Drug Profile
vortioxetine - Drug Profile
lurasidone hydrochloride - Drug Profile
brexpiprazole - Drug Profile
cariprazine - Drug Profile
TGFK-07AD - Drug Profile
(pipamperone + citalopram) - Drug Profile
INASTR-001 - Drug Profile
trazodone hydrochloride - Drug Profile
(aripiprazole + sertraline) - Drug Profile
amitifadine - Drug Profile
Rellidep - Drug Profile
edivoxetine - Drug Profile
verucerfont - Drug Profile
RG-1578 - Drug Profile
TGBA-01AD - Drug Profile
SCH-900978 - Drug Profile
tramadol - Drug Profile
RG-7090 - Drug Profile
cutamesine - Drug Profile
GLYX-13 - Drug Profile
CERC-301 - Drug Profile
(samidorphan + buprenorphine hydrochloride) - Drug Profile
LY-2940094 - Drug Profile
HT-2157 - Drug Profile
esketamine - Drug Profile
MSI-195 - Drug Profile
diazoxide - Drug Profile
tedatioxetine - Drug Profile
BCI-632 - Drug Profile
AN-788 - Drug Profile
NSI-189 - Drug Profile
DSP-1053 - Drug Profile
BCI-838 - Drug Profile
BCI-1038 - Drug Profile
BCI-1206 - Drug Profile
BCI-1283 - Drug Profile
NRX-1074 - Drug Profile
SEP-363856 - Drug Profile
LY-03005 - Drug Profile
NSI-189 - Drug Profile
NRX-1050 - Drug Profile
SUVN-911 - Drug Profile
NR2B Program For Major Depression - Drug Profile
NLF-NEU - Drug Profile
Major Depression Program - Drug Profile
BN-201 - Drug Profile
Ketamine Metabolites - Drug Profile
BN-204 - Drug Profile
BN-206 - Drug Profile
RP-5063 - Drug Profile
EDG-005 - Drug Profile
Drug For Depression - Drug Profile
BN-205 - Drug Profile
Major Depressive Disorder - Recent Pipeline Updates
Major Depressive Disorder - Dormant Projects
Major Depressive Disorder - Discontinued Products
Major Depressive Disorder - Product Development Milestones
Featured News & Press Releases

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Table


Number of Products under Development for Major Depressive Disorder, H1 2014
Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Development by Companies, H1 2014 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Comparative Analysis by Unknown Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Development by Companies, H1 2014 (Contd..1)
Products under Development by Companies, H1 2014 (Contd..2)
Products under Development by Companies, H1 2014 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2014
Major Depressive Disorder - Pipeline by Johnson & Johnson, H1 2014
Major Depressive Disorder - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014
Major Depressive Disorder - Pipeline by AstraZeneca PLC, H1 2014
Major Depressive Disorder - Pipeline by Eli Lilly and Company, H1 2014
Major Depressive Disorder - Pipeline by Alkermes Plc, H1 2014
Major Depressive Disorder - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014
Major Depressive Disorder - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014
Major Depressive Disorder - Pipeline by Neurocrine Biosciences, Inc., H1 2014
Major Depressive Disorder - Pipeline by Richter Gedeon Nyrt., H1 2014
Major Depressive Disorder - Pipeline by H. Lundbeck A/S, H1 2014
Major Depressive Disorder - Pipeline by OPKO Health, Inc., H1 2014
Major Depressive Disorder - Pipeline by Neuralstem, Inc., H1 2014
Major Depressive Disorder - Pipeline by Suven Life Sciences Ltd., H1 2014
Major Depressive Disorder - Pipeline by e-Therapeutics plc, H1 2014
Major Depressive Disorder - Pipeline by Intas Pharmaceuticals Ltd., H1 2014
Major Depressive Disorder - Pipeline by Angelini Group, H1 2014
Major Depressive Disorder - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H1 2014
Major Depressive Disorder - Pipeline by Dart NeuroScience LLC, H1 2014
Major Depressive Disorder - Pipeline by M\'s Science Corporation, H1 2014
Major Depressive Disorder - Pipeline by BrainCells Inc., H1 2014
Major Depressive Disorder - Pipeline by Otsuka Holdings Co., Ltd., H1 2014
Major Depressive Disorder - Pipeline by Reviva Pharmaceuticals Inc., H1 2014
Major Depressive Disorder - Pipeline by Luye Pharma Group Ltd., H1 2014
Major Depressive Disorder - Pipeline by Euthymics Bioscience, Inc., H1 2014
Major Depressive Disorder - Pipeline by Naurex, Inc., H1 2014
Major Depressive Disorder - Pipeline by PharmaNeuroBoost NV, H1 2014
Major Depressive Disorder - Pipeline by NeurOp Corporation, H1 2014
Major Depressive Disorder - Pipeline by Edgemont Pharmaceuticals, LLC, H1 2014
Major Depressive Disorder - Pipeline by Methylation Sciences Inc., H1 2014
Major Depressive Disorder - Pipeline by Sunovion Pharmaceuticals Inc., H1 2014
Major Depressive Disorder - Pipeline by BRAINco Biopharma, S.L., H1 2014
Major Depressive Disorder - Pipeline by Bionure, H1 2014
Major Depressive Disorder - Pipeline by Cerecor Inc., H1 2014
Major Depressive Disorder - Pipeline by nLife Therapeutics, S.L., H1 2014
Major Depressive Disorder - Pipeline by Aniona ApS, H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Major Depressive Disorder Therapeutics - Recent Pipeline Updates, H1 2014
Major Depressive Disorder - Dormant Projects, H1 2014
Major Depressive Disorder - Dormant Projects (Contd..1), H1 2014
Major Depressive Disorder - Dormant Projects (Contd..2), H1 2014
Major Depressive Disorder - Dormant Projects (Contd..3), H1 2014
Major Depressive Disorder - Dormant Projects (Contd..4), H1 2014
Major Depressive Disorder - Discontinued Products, H1 2014
Major Depressive Disorder - Discontinued Products (Contd..1), H1 2014
Major Depressive Disorder - Discontinued Products (Contd..2), H1 2014

List of Chart


Number of Products under Development for Major Depressive Disorder, H1 2014
Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Products, H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *